您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Robatumumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Robatumumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:934235-44-6
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品名称
Sch 717454
19D12
产品介绍
Robatumumab (Sch 717454) 是一种 anti-humanIGF-1R(胰岛素样生长因子 1 受体) 抗体。Robatumumab 具有抗肿瘤活性和抗癌细胞增殖活性。Robatumumab 可用于骨肉瘤和尤文肉瘤的研究。
生物活性

Robatumumab (Sch 717454) is an anti-humanIGF-1R(insulin-like growth factorreceptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity tocancercells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research[1][2].

体外研究
(In Vitro)

Robatumumab (0.02-80 nM; 0.5 or 4 h) downregulates IGF-IR and inhibits both basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells[2].

Western Blot Analysis[2]

Cell Line:SK-N-FI cells
Concentration:0.02-80 nM
Incubation Time:0.5 or 4 hours
Result:Inhibited the IGF-I–stimulated phosphorylation of IGF-IR after treatment 0.5 h.
Resulted in both inhibition of IGF-IR phosphorylation and receptor downregulation after treatment 4 h.
Resulted in a dose-dependent inhibition of the IGF-I–stimulated IRS-1 phosphorylation.
体内研究
(In Vivo)

Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model[2].
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo[2].
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect[2].

Animal Model:Nude mice inoculated with SK-N-FI tumor cells[2]
Dosage:0.04 or 0.1 mg/mouse
Administration:Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days
Result:Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group.
Animal Model:Nude mice inoculated with SJSA-1 osteosarcoma[2]
Dosage:0.02, 0.1 or 0.5 mg/mouse
Administration:Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days
Result:Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment.
Animal Model:Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells[2]
Dosage:0.1 or 0.5 mg/mouse
Administration:Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days
Result:Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.
Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model.
Animal Model:Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma[2]
Dosage:0.1 or 0.5 mg/mouse
Administration:Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks
Result:Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.
Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft.
Animal Model:Nude mice inoculated with SJSA-1 osteosarcoma[2]
Dosage:0.5 mg/mouse
Administration:Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation
Result:Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1.
Clinical Trial
CAS 号

934235-44-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.